TGFB1: Transforming growth factor beta-1 proprotein
Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively. {ECO:0000269|PubMed:29109152, ECO:0000303|PubMed:27252363}.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TGFB1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
- Other 1
| Fresolimumab | Phase 2 | Sanofi | Antibody | Inhibitor | 0 |
| LY-2382770 | Phase 2 | Eli Lilly | Other | Inhibitor | 0 |
| Metelimumab | Phase 2 | — | Antibody | Inhibitor | 0 |
- Camurati-Engelmann disease0.80
- Inflammatory bowel disease, immunodeficiency, and encephalopathy0.69
- Myelodysplastic syndrome0.59
- Coronary artery disorder0.58
- Anemia0.58
- Beta thalassemia0.54
- Cancer0.53
- Cardiovascular disorder0.53
- Myocardial infarction0.50
- Coronary atherosclerosis0.49
- Heart disorder0.49
- Hematuria0.49
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1795178, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01137, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets